2. Disease Areas
  3. Cancer Blood or Cardio-cerebrovascular Disease
  4. Leukemia/Lymphoma/Myeloma Blood Disease
  5. Leukemia/Lymphoma/Myeloma
  6. Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia (ALL) is an aggressive hematologic malignancy characterized by the rapid proliferation of immature lymphoid cells (lymphoblasts) in the bone marrow and peripheral blood, leading to suppression of normal hematopoiesis. It primarily affects children but can also occur in adults, with a higher incidence in young individuals. The disease involves the uncontrolled growth of abnormal lymphocytes that infiltrate the bone marrow, peripheral blood, and often spread to extramedullary sites such as lymph nodes, liver, spleen, and central nervous system. This results in clinical manifestations including fatigue, pallor, fever, bleeding or bruising, lymphadenopathy, and bone pain due to bone marrow replacement and impaired production of normal blood cells. Without prompt treatment, ALL progresses rapidly and can lead to life-threatening complications such as infection, hemorrhage, organ failure, and death. T-cell acute lymphoblastic leukemia (T-ALL) is a subtype involving malignant transformation of T-cell precursors, exhibiting similar aggressive features and systemic involvement.

Acute Lymphoblastic Leukemia (31):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-112654
    GCN2iB 2183470-12-2 99.83%
    GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC50 of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy.
    GCN2iB
  • HY-173523
    KI-CDK9d-32 3054009-82-1 99.03%
    KI-CDK9d-32 is a highly selective and potent CDK9 PROTAC degrader (DC50: 0.89 nM). KI-CDK9d-32 promotes the ubiquitination and degradation of CDK9. KI-CDK9d-32 inhibits the MYC pathway and disrupts nucleolar homeostasis. KI-CDK9d-32 exhibits anticancer activity against acute lymphoblastic leukemia and pancreatic cancer. (Pink: CDK9 ligand (HY-153718); Blue: E3 ligase CRBN ligand (HY-163233); Black: Linker (HY-W011657); E3 ligase CRBN ligand-linker conjugate (HY-173525)).
    KI-CDK9d-32
  • HY-N6893
    Ergolide 54999-07-4 99.48%
    Ergolide is an orally active dual inhibitor targeting NF-κB/p65 and NLRP3. Ergolide blocks the NF-κB signaling pathway and the nuclear translocation of p65, and irreversibly binds to the NACHT domain of NLRP3 to inhibit inflammasome assembly. Ergolide significantly reduces the production of inflammatory mediators (e.g., NO, PGE2) and cytokines, induces cancer cell apoptosis, autophagy and ROS generation. Ergolide also enhances the anti-tumor effect of vincristine. Ergolide alleviates acute lung injury via an NLRP3-dependent mechanism, and effectively improves the survival rate and behavioral function of septic mice and inflammatory zebrafish models. Ergolide is used in the research of metastatic uveal melanoma, neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease), sepsis and acute lymphoblastic leukemia.
    Ergolide
  • HY-161828
    JWZ-5-13 3103763-70-5 98.19%
    JWZ-5-13 is a CDK7 PROTAC degrader. JWZ-5-13 inhibits the proliferation of cancer cells. JWZ-5-13 is applicable to the research of ovarian cancer, diffuse large B-cell lymphoma, acute T-lymphoblastic leukemia and non-small cell lung cancer.
    JWZ-5-13
  • HY-P9959
    Inotuzumab ozogamicin 635715-01-4 99.7%
    Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22+ B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia.
    Inotuzumab ozogamicin
  • HY-185557
    LLC0424N 3063448-59-6
    LLC0424N is a negative control compound designed by methylating the thalidomide moiety of LLC0424 (HY-161574). LLC0424N shows does not induce NSD2 degradation and inhibit growth of acute lymphoblastic leukemia cells with NSD2 mutation. LLC0424N can be used for the research of acute lymphoblastic leukemia.
    LLC0424N
  • HY-182081
    Tubulin polymerization-IN-90 3006800-41-2
    Tubulin polymerization-IN-90 is a tubulin polymerization inhibitor. Tubulin polymerization-IN-90 disrupts tubulin polymerization by binding to the nocodazole-binding site on β-tubulin. Tubulin polymerization-IN-90 induces the release of extracellular vesicles marked by the tetraspanin CD63. Tubulin polymerization-IN-90 induces the release of IL-8 from cells. Tubulin polymerization-IN-90 reduces the viability of cancer cells. Tubulin polymerization-IN-90 can be used in the research of cancers such as acute T-lymphoblastic leukemia.
    Tubulin polymerization-IN-90
  • HY-P992058
    Leukotuximab
    Leukotuximab (ART-140; EGX-040) is an anti-JL1 mAb and an anti-leukemic agent. Leukotuximab targets the JL1 epitope of CD43 and exerts cytotoxic effects on JL1-positive leukemia cells. Except for thymocytes and some bone marrow mononuclear cells, Leukotuximab causes no damage to most normal tissues. Leukotuximab can be used in the research of acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome.
    Leukotuximab
  • HY-176528
    PROTAC ERK5 degrader-1 2919963-24-7 99.58%
    PROTAC ERK5 degrader-1 (compound 2) is a bifunctional ERK5 PROTAC degrader. PROTAC ERK5 degrader-1 induces ERK5 degradation via VHL-mediated proteasome pathway in MOLT-4 cells. PROTAC ERK5 degrader-1 can be used for the study of a disease or disorder characterized by aberrant ERK5 activity, such as acute lymphoblastic leukemia.
    PROTAC ERK5 degrader-1
  • HY-164466A
    CAD204520 dihydrochloride 2682205-21-4 99.26%
    CAD204520 dihydrochloride, a SERCA inhibitor (IC50 = 0.34 μM), targets mutated over wild type NOTCH1 proteins in T-cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL). CAD204520 dihydrochloride can be used for T-ALL and MCL research.
    CAD204520 dihydrochloride
  • HY-183870
    NCO-90 1382354-18-8
    NCO-90 is a selective SIRT2 inhibitor with an IC50 of 1.0 μM. NCO-90 induces Apoptosis via Caspase activation and mitochondrial superoxide anion production, and also induces Autophagic cell death by increasing LC3-II levels and autophagosome accumulation. NCO-90 exhibits anticancer activity against leukemia. NCO-90 can be used in research related to acute lymphoblastic leukemia and acute myeloid leukemia.
    NCO-90
  • HY-P992275
    Anti-Nicastrin Antibody (A5226A)
    Anti-Nicastrin Antibody (A5226A) is a monoclonal antibody against Nicastrin and an inhibitor of γ-secretase. Anti-Nicastrin Antibody (A5226A) recognizes the fully glycosylated mature presenilin enhancer in the active γ-secretase complex and inhibits its activity via competition for substrate binding. Anti-Nicastrin Antibody (A5226A) abrogates the growth of cancer cells dependent on γ-secretase activity. Anti-Nicastrin Antibody (A5226A) serves as an imaging tool to visualize the endocytic trafficking of active γ-secretase, and also acts as a detection reagent to evaluate the endocytic efficiency of γ-secretase. Anti-Nicastrin Antibody (A5226A) can be used in studies related to non-small cell lung cancer, T-cell acute lymphoblastic leukemia and Alzheimer's disease.
    Anti-Nicastrin Antibody (A5226A)
  • HY-183071
    CDK7 ligand 3 3040999-61-6
    CDK7 ligand 3 is a target protein ligand for CXJ2080 (HY-183070), which be used for the research of acute leukemia.
    CDK7 ligand 3
  • HY-183070
    CXJ2080
    CXJ2080 is a selective PROTAC-based CDK7 degrader with a DC50 of 0.88 nM. CXJ2080 recruits VHL E3 ligase to induce ubiquitin-proteasome-dependent CDK7 degradation, disrupts the CDK7-cyclin H-MAT1 complex, suppresses CDK7-dependent phosphorylation of RNA polymerase II CTD Ser5, CDK1 Thr161, and CDK2 Thr160. CXJ2080 activates the p53-p21 axis, suppresses MYC-driven signaling, induces leukemia cell cycle arrest, apoptosis, and differentiation, reduces CD117 expression, spares platelets and normal PBMCs, maintains sustained CDK7 degradation post-washout. CXJ2080 can be used for the research of acute leukemia.
    CXJ2080
  • HY-185459
    PCIP-1
    PCIP-1 is a PARP2 inhibitor. PCIP-1 recruits BET proteins to PARP2 to inhibit DNA repair, acts via event-driven pharmacology, and does not inhibit PARP-catalyzed PARylation. PCIP-1 inhibits DNA repair, thereby inducing synthetic lethality in homologous recombination-deficient cancer cells and increasing the sensitivity of PARP1-knockout cells. PCIP-1 can be used in the research of homologous recombination-deficient cancers, T-cell acute lymphoblastic leukemia, and BRCA-mutant cancers.
    PCIP-1
  • HY-181768
    HDAC3-IN-8 2763368-90-5
    HDAC3-IN-8 is a selective inhibitor targeting HDAC1, HDAC2 and HDAC3, with IC50 values of 3.52 nM for HDAC1, 15.14 nM for HDAC2 and 0.38 nM for HDAC3. HDAC3-IN-8 shows high selectivity for HDAC3 and exerts its effect by inhibiting histone deacetylase activity. HDAC3-IN-8 can be used to construct HDAC3-targeted PROTAC degrader (HY-181767) and is suitable for the research of acute myeloid leukemia (AML).
    HDAC3-IN-8
  • HY-112904A
    XRK3F2 free base 2375193-42-1
    XRK3F2 free base is a p62 (sequestosome-1) ZZ domain inhibitor that has specificity for the p62-ZZ domain over other p62 signaling domains. XRK3F2 free base blocks TNFα effects and upregulation in bone marrow stromal cells, and induces multiple myeloma cell apoptosis. XRK3F2 free base can be used for the research of multiple myeloma bone disease, acute myeloid leukemia, and multiple myeloma.
    XRK3F2 free base
  • HY-179466
    BKT300 2551033-16-8
    BKT300 is a potent and selective protein regulator of cytokinesis 1 (PRC1) inhibitor. BKT300 inhibits PRC1 dephosphorylation at T481, disrupts actin and microtubule formation, induces G2/M cell cycle arrest, triggers mitotic catastrophe, and promotes apoptosis, thereby inhibiting proliferation and migration of acute myeloid leukemia (AML) cells while sparing normal cells. BKT300 inhibits tumor growth in mouse xenograft AML models. BKT300 can be used for the research of AML.
    BKT300
  • HY-P991924
    CO-1
    CO-1 is an IgG4 anti-CD47 antibody. CO-1 not only enhances themacrophage phagocytosis activity but also induces a unique and fast form of programmed celldeath (PCD) in cancer cells directly through ligation of CD47. CO-1 has anticancer activity against hematologic malignancies such as acute lymphoblastic leukemia.
    CO-1
  • HY-P991896
    AT1412
    AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells [1] .
    AT1412